

This Page Is Inserted by IFW Operations
and is not a part of the Official Record

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images may include (but are not limited to):

- BLACK BORDERS
- TEXT CUT OFF AT TOP, BOTTOM OR SIDES
- FADED TEXT
- ILLEGIBLE TEXT
- SKEWED/SLANTED IMAGES
- COLORED PHOTOS
- BLACK OR VERY BLACK AND WHITE DARK PHOTOS
- GRAY SCALE DOCUMENTS

IMAGES ARE BEST AVAILABLE COPY.

**As rescanning documents *will not* correct images,
please do not report the images to the
Image Problem Mailbox.**

PCTWORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau

INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification ⁶ : A61K 7/06	A1	(11) International Publication Number: WO 95/35085 (43) International Publication Date: 28 December 1995 (28.12.95)
(21) International Application Number: PCT/US95/07626 (22) International Filing Date: 16 June 1995 (16.06.95) (30) Priority Data: 08/261,475 17 June 1994 (17.06.94) US (71) Applicant: PROCYTE CORPORATION [US/US]; Suite 210, 12040-115th Avenue, N.E., Kirkland, WA 98034-6900 (US). (72) Inventors: PALLENBERG, Alexander, J.; 20024-330th Avenue, N.E., Duvall, WA 98019 (US). PATT, Leonard, M.; 12016-40th Avenue, N.E., Seattle, WA 98125 (US). TRACHY, Ronald, E.; 9618 N.E. 198th Street, Bothell, WA 98011 (US). (74) Agents: HERMANN, Karl, R. et al.; Seed and Berry, 6300 Columbia Center, 701 Fifth Avenue, Seattle, WA 98104-7092 (US).		(81) Designated States: AM, AU, BB, BG, BR, BY, CA, CN, CZ, EE, FI, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LT, LV, MD, MG, MN, MW, MX, NO, NZ, PL, RO, RU, SD, SG, SI, SK, TJ, TT, UA, UZ, VN, European patent (AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG), ARIPO patent (KE, MW, SD, SZ, UG). Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>
(54) Title: STIMULATION OF HAIR GROWTH BY PEPTIDE-COPPER COMPLEXES (57) Abstract Peptide-copper complexes are disclosed which stimulate the growth of hair on warm-blooded animals. In one aspect of this invention, the peptide-copper complexes are dipeptides or tripeptides chelated to copper at a molar ratio ranging from about 1:1 to 3:1, with the second position of the peptide from the amino terminus being histidine, arginine or a derivative thereof. The peptide-copper complexes may be formulated for administration by, for example, topical application or injection. Any affliction associated with hair loss, including hair loss associated with both androgenetic and secondary alopecia, may be treated with the peptide-copper complexes of this invention.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	GB	United Kingdom	MR	Mauritania
AU	Australia	GE	Georgia	MW	Malawi
BB	Barbados	GN	Guinea	NE	Niger
BE	Belgium	GR	Greece	NL	Netherlands
BF	Burkina Faso	HU	Hungary	NO	Norway
BG	Bulgaria	IE	Ireland	NZ	New Zealand
BJ	Benin	IT	Italy	PL	Poland
BR	Brazil	JP	Japan	PT	Portugal
BY	Belarus	KE	Kenya	RO	Romania
CA	Canada	KG	Kyrgyzstan	RU	Russian Federation
CF	Central African Republic	KP	Democratic People's Republic of Korea	SD	Sudan
CG	Congo	KR	Republic of Korea	SE	Sweden
CH	Switzerland	KZ	Kazakhstan	SI	Slovenia
CI	Côte d'Ivoire	LI	Liechtenstein	SK	Slovakia
CM	Cameroon	LK	Sri Lanka	SN	Senegal
CN	China	LU	Luxembourg	TD	Chad
CS	Czechoslovakia	LV	Latvia	TG	Togo
CZ	Czech Republic	MC	Monaco	TJ	Tajikistan
DE	Germany	MD	Republic of Moldova	TT	Trinidad and Tobago
DK	Denmark	MG	Madagascar	UA	Ukraine
ES	Spain	ML	Mali	US	United States of America
FI	Finland	MN	Mongolia	UZ	Uzbekistan
FR	France			VN	Viet Nam
GA	Gabon				

STIMULATION OF HAIR GROWTH BY PEPTIDE COPPER COMPLEXES

Technical Field

- 5 This invention relates generally to peptide-copper complexes and, more specifically, to compositions containing peptide-copper complexes for stimulating hair growth.

Background of the Invention

- 10 Hair loss is a prevalent affliction of many humans, the most common being androgenetic alopecia (AGA) where males lose scalp hair as they get older (i.e., male pattern baldness). Other hair loss afflictions include alopecia areata (AA), female pattern baldness and hair loss secondary to chemotherapy and/or radiation treatment (i.e., secondary alopecia).

- 15 Hair is normally divided into two types: "terminal" and "vellus". Terminal hair is coarse, pigmented hair which arises from follicles which are developed deep within the dermis. Vellus hairs are typically thin, non-pigmented hairs which grow from hair follicles which are smaller and located superficially in the dermis. As alopecia progresses, there is a change from terminal to vellus type hair. Other changes that
20 contribute to alopecia are alterations in the growth cycle of hair. Hair typically progresses through three cycles, anagen (active hair growth), catagen (transition phase), and telogen (resting phase during which the hair shaft is shed prior to new growth). As baldness progresses, there is a shift in the percentages of hair follicles in each phase with the majority shifting from anagen to telogen. The size of hair follicles is also known to
25 decrease while the total number remains relatively constant.

- A variety of procedures and drugs have been utilized in an attempt to treat hair loss. A common technique involves hair transplantation. Briefly, plugs of skin containing hair are transplanted from areas of the scalp where hair was growing to bald or balding areas of the scalp. This procedure, however, is time-consuming and relatively
30 painful. Other approaches include ultra-violet radiation and exercise therapy.

- More recently, the stimulating hair growth has been achieved, although with limited success, by drug therapy. One of the most well-recognized hair-growth agents is sold under the tradename "Minoxidil", as disclosed in U. S. Patent No. 4,596,812 assigned to Upjohn. However, while the results generated through the use of Minoxidil
35 have appeared promising, there is still a need in the art for improved compositions capable of stimulating the growth of hair in warm-blooded animals. To this end, certain

peptide-copper complexes have been found to be effective hair-growth agents. For example, U.S. Patent Nos. 5,177,061, 5,120,831 and 5,214,032 disclose certain peptide-copper complexes which are effective in stimulating the growth of hair in warm-blooded animals.

- 5 While significant progress has been made in the stimulation of hair-growth by drug treatment, there is still a need in the art for compounds which have greater stimulatory effect on hair growth. The present invention fulfills this need, while further providing other related advantages.

10 Summary of the Invention

- Briefly stated, the present invention is directed to peptide-copper complexes, and compositions containing the same, for stimulating the growth of hair in warm-blooded animals. Compositions of this invention include one or more peptide-copper complexes in combination with an acceptable carrier or diluent. As used herein, the term "copper"
- 15 is used to designate copper(II) (i.e., Cu^{+2}).

- The peptide-copper complexes of this invention are administered to an animal in need thereof in a manner which results in the application of an effective amount of the peptide-copper complex. As used herein, the term "effective amount" means an amount of the peptide-copper complex which stimulates hair growth associated with a hair-loss
- 20 afflications (such as male pattern baldness) or caused by a hair-loss insult (such as radiation or chemotherapy). Thus, the peptide-copper complexes may be used prophylactically, as well as therapeutically and cosmetically. Administration of the peptide-copper complexes is preferably by topical application, although other avenues of administration may be employed, such as injection (e.g., intramuscular, intravenous,
- 25 subcutaneous and intradermal). Typically, the peptide-copper complexes of this invention are formulated as a solution, cream or gel for topical application, or as a solution for injection, and include one or more acceptable carriers or diluents.

- As used herein, the term "peptide-copper complex" means a peptide having at least two amino acids (or amino acid derivatives) chelated to copper, wherein the second
- 30 amino acid from the amino terminus of the peptide is histidine, arginine or a derivative thereof. Such peptide-copper complexes have the following general structure A:

A: $[\text{R}_1\text{-R}_2]:\text{copper(II)}$

 wherein:

R_1 is an amino acid or an amino acid derivative; and

- 35 R_2 is histidine, arginine or a derivative thereof.

The peptide-copper complexes of this invention have a ratio of peptide to copper ranging from about 1:1 to about 3:1, and more preferably from about 1:1 to about 2:1. In short, a component of the peptide occupies at least one coordination site of the copper ion, and multiple peptides may be chelated to a single copper ion.

- 5 In a preferred embodiment, the peptide-copper complex comprises a further chemical moiety linked to the R₂ moiety of structure A by an amide or peptide bond. (i.e., -C(=O)NH-). In this embodiment, the peptide-copper complex has the following structure B:

- 10 B: [R₁-R₂-R₃]:copper(II)
wherein:
R₁ is an amino acid or amino acid derivative;
R₂ is histidine, arginine or a derivative thereof; and
R₃ is a chemical moiety joined to R₂ by an amide bond.

- 15 In a further preferred embodiment, R₃ of structure B is at least one amino acid joined to R₂ by a peptide bond. In this embodiment, the peptide-copper complex has the following structure C:

- C: [R₁-R₂-R₃]:copper(II)
wherein:
R₁ is an amino acid or amino acid derivative;
20 R₂ is histidine, arginine or a derivative thereof; and
R₃ is an amino acid or amino acid derivative joined to R₂ by a peptide bond, with the proviso that R₁ is not glycyl, alanyl, seryl or valyl when R₂ is histidyl or (3-methyl)histidyl and R₃ is lysine, lysyl-prolyl-valyl-phenylalanyl-valine, lysyl-valyl-phenylalanyl-valine, lysyl-tryptophan, or lysyl-(glycyl)₁₋₂-tryptophan, and with the
25 further proviso that R₁ is not lysyl when R₂ is histidyl or (3-methyl)histidyl and R₃ is glycine, glycyl-prolyl-valyl-phenylalanyl-valine, glycyl-valyl-phenylalanyl-valine, glycyl-tryptophan, or glycyl-(glycyl)₁₋₂-tryptophan

- 30 In still a further embodiment of the present invention, an additional chelating agent may be added to the peptide-copper complexes disclosed above to form a ternary peptide-copper-chelating agent complex.

Other aspects of the present invention will become evident upon reference to the following detailed description.

Detailed Description of the Invention

This invention is directed to peptide-copper complexes which stimulate the growth of hair on warm-blooded animals. Such complexes are typically administered as a composition containing acceptable diluents and/or carriers. Administration is preferably by topical application directly to the area where stimulation of hair growth is desired, such as the scalp, although other routes of administration may be employed.

The peptide-copper complexes of this invention may be used to stimulate hair growth in animals (including humans) afflicted with androgenetic alopecia (AGA). Animals afflicted with this condition are usually male, and the condition results in the loss of scalp hair with age (also called "male pattern baldness"). Thus, the peptide-copper complexes may be administered in order to stimulate hair growth, thereby eliminating or reducing the severity of hair loss and/or the speed at which AGA progresses. Other hair loss afflictions include alopecia areata (AA), female pattern baldness and hair loss secondary to chemotherapy and/or radiation treatment (i.e., secondary alopecia). In the case of secondary alopecia, the peptide-copper complexes may be used in advance of certain hair-loss insults, such as chemotherapy or radiation regimens, to stimulating hair growth prior to the insult and thereby reduce the amount of hair loss resulting therefrom.

As mentioned above, the peptide-copper complexes of the present invention have at least two amino acids (or amino acid derivatives), one of which is histidine, arginine or a derivative thereof. In this context, the peptide-copper complexes have structure A as identified above. For example, when R₁ is an amino acid and R₂ is histidyl, or when R₁ is an amino acid and R₂ is arginine, the peptide copper complex has the following structures D and E, respectively:

D: [(amino acid)-histidine]:copper(II)


E: [(amino acid)-arginine]:copper(II)

As used in structure A above, the terms "amino acid" and "amino acid derivative" are defined hereinbelow. An amino acid of this invention includes any carboxylic acid having an amino moiety, including (but not limited to) the naturally occurring α -amino acids (in the following listing, the single letter amino acid designations are given in parentheses): alanine (A), arginine (R), asparagine (N), aspartic acid (D), cysteine (C), glutamine (Q), glutamic acid (E), glycine (G), histidine (H), isoleucine (I), leucine (L), lysine (K), methionine (M), phenylalanine (F), proline (P), serine (S), threonine (T), tryptophan (W), tyrosine (Y) and valine (V). Other naturally occurring amino acids

include (but are not limited to) hydroxyproline and γ -carboxyglutamate. In a preferred embodiment, the amino acid is a naturally occurring α -amino acid having an amino moiety (i.e., the $-\text{NH}_2$ group, rather than a secondary amine, $-\text{NH}-$, such as present in proline) attached to the α -carbon of the amino acid which, when chelated to copper, occupies a coordination site thereof. As used herein, "hydrophilic amino acids" include (but are not limited to) the amino acids selected from K, R, H, D, E, N, Q, C, M, S and T.

An amino acid derivative of this invention includes any compound having the structure:


10



wherein R is a derivative of a naturally occurring amino acid side chain. In one embodiment, R_1 and R_2 in the above structure may be selected from hydrogen, a substituted or unsubstituted, straight chain, branched or cyclic, saturated or unsaturated alkyl moiety containing from 1-20 carbon atoms, and a substituted or unsubstituted aryl moiety containing from 6-20 carbon atoms (including heteroaromatic moieties). In a preferred embodiment, R_1 and R_2 may be selected from the chemical moieties identified in Table 1 below.

20

Table 1
Amino Acid Derivatives



Where $\text{R}_2 = \text{H}$ or the following moieties:


$-(\text{CH}_2)_n\text{CH}_3$ where $n = 1-20$

$-(\text{CH}_2)_n\text{CH}(\text{CH}_3)(\text{CH}_2)_m\text{CH}_3$ where $n, m = 0-20$
(when $n = 0$, $m \neq 0$ or 1 and when $n = 1$, $m \neq 0$)






$-(\text{CH}_2)_n\text{NH}_2$ where $n = 1-20$ ($n \neq 4$)

$-(\text{CH}_2)_n\text{CONH}_2$ where $n = 3-20$



$-(\text{CH}_2)_n\text{COOH}$ where $n = 3-20$

$-(\text{CH}_2)_n$  where $n = 2-20$


6



And where $R_1 = \text{H}$ or the following moieties:




Histidine derivatives of this invention include compounds having the structure:



5 where $n = 1-20$, and X and Y are independently selected from alkyl moieties containing from 1-12 carbon atoms or an aryl moiety containing from 6-12 carbon atoms. In preferred embodiments, n is 1, X is methyl and Y is H (i.e., 3-methyl histidyl) or X is H and Y is methyl (i.e., 5-methyl histidine).

Similarly, arginine derivatives of this invention include compounds having the structure:




where $n = 1-20$ (excluding $n = 3$).

In another embodiment of this invention, the peptide-copper complexes of structure A further comprise a chemical moiety linked to the R_2 moiety by an amide or peptide bond. (i.e., $-C(=O)NH-$). The peptide-copper complexes of this embodiment are depicted above as structure B. As used herein, a chemical moiety (i.e., R_3) linked to the R_2 moiety by an amide bond includes any chemical moiety having an amino group capable of forming an amide linkage with the carboxyl terminus of R_2 (i.e., the carboxyl terminus of histidine, arginine, or derivatives thereof). Suitable R_3 moieties include (but are not limited to) $-NH_2$, alkylamino moieties having from 1-20 carbon atoms and arylamino moieties having from 6-20 carbon atoms, as well as amino acids and derivatives thereof. As used herein, "alkylamino moieties" include alkyl moieties containing an amino moiety, wherein the alkyl moiety is as defined above, and includes (but is not limited to) octyl amine and propyl amine. Similarly, "arylamino moieties" include aryl moieties containing an amino moiety, wherein the aryl moiety is as defined above, and includes (but is not limited to) benzylamine and benzyl- $(CH_2)_{1-14}$ -amine. Further examples of suitable chemical moieties having amino groups capable of forming an amide linkage with the carboxyl terminus of R_2 include polyamines such as spermine and spermidine.

For example, in structure B when R_1 is an amino acid, R_2 is histidine or arginine, and R_3 is an amino moiety, the peptide-copper complex has the following structures F and G, respectively:



Similarly, when R_1 is an amino acid, R_2 is histidine or arginine, and R_3 is an alkylamino moiety, the peptide-copper complex has the following structures H and I, respectively:



In yet a further embodiment (as represented by structure C above), the R_3 moiety of structure B is at least one an amino acid or an amino acid derivative as defined above. In a preferred embodiment, R_3 is a naturally occurring α -amino acid joined to R_2 by a peptide bond. For example, when R_1 and R_3 of structure C are amino acids, and R_2 is histidine or arginine, the peptide-copper complexes of this invention have the following structures J and K, respectively:

J: [(amino acid)-histidine-(amino acid)]:copper(II)

K: [(amino acid)-arginine-(amino acid)]:copper(II)

It should be understood that while only a single amino acid is depicted in the R₃ position of structures H and I, other chemical moieties may also be present, including additional amino acids and/or amino acid derivatives. For example, R₃ in structures H and I may be a peptide such as phenylalanine-phenylalanine, (glycyl)_n-tryptophan where n = 1-4, prolyl-X₁-phenylalanyl-X₂ or X₁-phenylalanyl-X₂ where X₁ and X₂ are selected from valine, alanine and glycine.

The peptides of the peptide-copper complexes of this invention may generally be classified as dipeptides (i.e., structure A), dipeptides with a chemical moiety attached to the carboxyl terminus via an amide bond (i.e., structure B) or as tripeptides (i.e., structure C above). In the case of peptide-copper complexes of structures B and C, additional chemical moieties, including amino acids, may be joined to the dipeptide or tripeptide to yield peptides containing four or more amino acids. For purpose of illustration, Table 2 presents various representative examples of peptide-copper complexes of this invention.

Table 2
Representative Peptide-Copper Complexes

Structure A:

glycyl-histidine:copper	alanyl-histidine:copper
glycyl-(3-methyl)histidine:copper	alanyl-(3-methyl)histidine:copper
glycyl-(5-methyl)histidine:copper	alanyl-(5-methyl)histidine:copper
glycyl-arginine:copper	alanyl-arginine:copper
(N-methyl)glycine-histidine:copper	(N-methyl)glycine-arginine:copper

Structure B:

glycyl-histidyl-NH ₂ :copper	glycyl-arginyl-NH ₂ :copper
glycyl-(3-methyl)histidyl-NH ₂ :copper	alanyl-(3-methyl)histidyl-NH ₂ :copper
glycyl-arginyl-NH ₂ :copper	alanyl-arginyl-NH ₂ :copper
(N-methyl)glycine-histidyl-NH ₂ :copper	(N-methyl)glycine-arginyl-NH ₂ :copper
glycyl-histidyl-NHoctyl:copper	glycyl-arginyl-NHoctyl:copper

Structure C:

glycyl-histidyl-lysine:copper	glycyl-arginyl-lysine:copper
glycyl-(3-methyl)histidyl-lysine:copper	glycyl-(5-methyl)histidyl-lysine:copper
alanyl-histidyl-lysine:copper	alanyl-arginyl-lysine:copper
alanyl-(3-methyl)histidyl-lysine:copper	alanyl-(5-methyl)histidyl-lysine:copper
glycyl-histidyl-phenylalanine:copper	glycyl-arginyl-phenylalanine:copper
glycyl-(3-methyl)histidyl-phenylalanine:copper	glycyl-(5-methyl)histidyl-phenylalanine:copper
alanyl-histidyl-phenylalanine:copper	alanyl-arginyl-phenylalanine:copper
alanyl-(3-methyl)histidyl-phenylalanine:copper	alanyl-(5-methyl)histidyl-phenylalanine:copper
glycyl-histidyl-lysyl-phenylalanyl-phenylalanyl:copper	glycyl-arginyl-lysyl-phenylalanyl-phenylalanyl:copper
glycyl-(3-methyl)histidyl-lysyl-phenylalanyl-phenylalanyl:copper	glycyl-(5-methyl)histidyl-lysyl-phenylalanyl-phenylalanyl:copper
(N-methyl)glycyl-histidyl-lysine:copper	(N-methyl)glycyl-arginyl-lysine:copper

Further examples of peptide-copper complexes of this invention are disclosed in U.S. Patent Nos. 5,118,665 and 5,164,367, as well as U.S. Patent Nos. 4,760,051; 5,466,054; 4,877,770; 5,177,061; 4,810,693; 4,767,753; 5,135,913; 5,023,237; 5,059,588 and 5,120,831, all of which are incorporated herein by reference in their entirety. Thus, the peptide-copper complexes disclosed in the above U.S. patents may be used to stimulate hair growth in animals (including humans) afflicted with androgenetic alopecia (AGA) or male pattern baldness, thereby eliminating or reducing the severity of hair loss and/or the speed at which AGA progresses. These peptide-copper complexes may also be used to treat other hair loss afflictions, include alopecia areata, female pattern baldness and hair loss secondary to chemotherapy and/or radiation treatment (i.e., secondary alopecia). In the case of secondary alopecia, the peptide-copper complexes may be used to stimulate hair growth prior to a insults which normally result in hair loss, such as chemotherapy or radiation regiments. Thus, the peptide-copper complexes of this invention may be used to prevent hair loss.

In the practice of this invention, the molar ratio of peptide to copper is greater than zero to one (e.g., 0.1:1, 0.2:1, etc.). The molar ratio of peptide to copper will depend, in part, on the number of copper coordination sites that are occupied by the

peptide. In a preferred embodiment, the molar ratio of peptide to copper ranges from about 1:1 to 3:1, and more preferably from about 1:1 to 2:1. For example, in the case of a tripeptide (such as GHF:copper), the preferred ratio of peptide to copper ranges from 1:1 to 2:1, with each tripeptide occupying three coordination sites of the copper.
5 Similarly, with a dipeptide (such as GH:copper), the preferred ratio of peptide to copper ranges from 1:1 to 3:1, with each dipeptide occupying two coordination sites of copper ion.

In another embodiment of this invention, a chelating agent may be added to the peptide-copper complex to form a ternary peptide-copper-chelating agent complex.
10 Suitable chelating agents include imidazole or imidazole-containing compounds, such as histidine, and sulfur containing amino acids, such as cysteine or methionine. Thus, if the peptide-copper complex is GHF:copper, histidine may be added to yield the ternary complex GHF:copper:histidine. However, to form such a ternary complex, the molar ratio of copper to peptide to chelating agent must be considered. For example, if the
15 ratio of peptide to copper is 2:1, the addition of a chelating agent to the peptide-copper complex, although possible, is difficult due to site occupancy by the peptide. However, by maintaining the ratio of peptide to copper near 1:1, a chelating group may readily be added to form the ternary complex. Thus, the preferred peptide to copper to chelating agent ratio is about 1:1:1.

20 While the chiral amino acids of the present invention (particularly the amino acids) have not been specifically designated, the present invention encompasses both the naturally occurring L-form, as well as the D-form. For example, any of the naturally occurring L-amino acids (or amino acid derivatives) disclosed herein may be replaced by a corresponding D-amino acid (or amino acid derivative).

25 In the practice of this invention, it is critical that the second position of the peptide (i.e., R₂ of structures A, B and C) is either histidine, arginine or a derivative thereof. It is believed that the superior effect of the peptide-copper complexes of the present invention is achieved, at least in part, by the binding of copper by an amino moiety of the amino acid side chain of histidine, arginine or derivative thereof. For
30 example, in the case of histidine, an amine group of the histidine imidazole ring occupies a coordination site of the copper (i.e., the residual valencies or unshared electrons of the amine group are shared with copper). In the case of arginine, an amine group of the amino acid side chain similarly occupies a coordination site of copper. The binding of R₂ to the copper atom is preferably combined with the coordination of an amine group
35 from the R₁ moiety of structures A, B and C, to yield the peptide-copper complex. Thus, a peptide of this invention chelates copper by donating the R₂ amine group, and

preferably both the R₁ and R₂ amine groups, to the peptide-copper complex. The peptide-copper complexes of structures B and C can further occupy additional coordination sites on copper. Specifically, the amine group of the amide bond of structure B and the peptide bond of structure C can occupy yet a further coordination sites.

As mentioned above, the peptide-copper complexes of this invention have utility as hair growth agents. More particularly, the peptide-copper complexes stimulates hair growth on warm-blooded animals. Thus, the peptide-copper complexes may be used to treat a variety of diseases states associated with hair loss, including (but not limited to) androgenetic alopecia (also know as male pattern baldness), alopecia areata and female pattern baldness. In these instances, the peptide-copper complexes stimulates the growth of hair after the onset of the hair-loss affliction. Alternatively, the peptide-copper complexes may be administered prophylactically for conditions such as secondary alopecia. For example, the complexes may be administered prior to an insult which normally results in hair loss, such as chemotherapy and/or radiation treatment. Thus, the peptide-copper complexes of this invention can be used to prevent hair loss.

Administration of the peptide-copper complexes of the present invention may be accomplished in any manner which will result in the delivery of an effective amount or dose of the peptide-copper complex to the animal, including delivery to the hair follicles. For example, administration may be by topical application directly to the scalp, or other area where hair stimulation is desired (hereinafter "the treatment area"). Alternatively, administration may also be accomplished by injection (such as intradermal injection) into the treatment area, including the scalp. Typically, the peptide-copper complexes are formulated as a composition containing the peptide-copper complex in combination with on or more acceptable carriers or diluents, including formulations which provide for the sustained release of the peptide-copper complexes over time.

In one embodiment, the peptide-copper complexes are formulated for intradermal injection to the treatment area. In such instances, such formulations preferably contain one or more peptide-copper complexes of this invention in combination with a suitable vehicle for intradermal injection, with the peptide-copper complex present in the composition at a concentration ranging from 100 µg to 2000 µg per 0.1 ml vehicle (i.e., 1.0 mg/ml to 20 mg/ml). Suitable vehicles for intradermal injection include (but are not limited to) saline and sterile water.

In another embodiment, the peptide-copper complexes are formulated for topical administration. Suitable topical formulations include one or more peptide-copper complexes in the form of a liquid, lotion, cream or and gel. Topical administration may

be accomplished by application directly on the treatment area. For example, such application may be accomplished by rubbing the formulation (such as a lotion or gel) onto the skin of the treatment area, or by spray application of a liquid formulation onto the treatment area. Any quantity of the topical formulation sufficient to accelerate the rate of hair growth or prevent subsequent hair loss is effective, and treatment may be repeated as often as the progress of hair growth indicates. Preferable, the topical compositions of this invention contain one or more peptide-copper complexes in an amount ranging from 0.1% to 20% by weight of the composition, and more preferably from 0.1% to 5% by weight of the composition.

In addition to carriers and diluents, the peptide-copper complexes may also be formulated to contain additional ingredients such as penetration enhancement agents and/or surface active agents. For example, topical formulations may contain 0.5% to 10% of one or more surface active agents (also called emulsifying agents). Non-ionic surface active agents and ionic surface active agents may be used for the purposes of the present invention. Examples of suitable non-ionic surface active agents are nonylphenoxypolyethoxy ethanol (Nonoxynol-9), polyoxyethylene oleyl ether (Brij-97), various polyoxyethylene ethers (Tritons), and block copolymers of ethylene oxide and propylene oxide of various molecular weights (such as Pluronic 68). Examples of suitable ionic surface active agents include sodium lauryl sulfate and similar compounds. Penetration enhancing agents may also be present in topical formulations. Suitable penetration enhancing agents include dimethyl sulfoxide (DMSO), urea and substituted urea compounds. In the case of a liquid formulation for topical administration, the concentration of the penetrating enhancing agent (such as DMSO) may range from 30% to 80% of liquid formulation.

The balance of the topical formulations may include inert, physiologically acceptable carriers or diluents. Suitable carriers or diluents include, but are not limited to, water, physiological saline, bacteriostatic saline (saline containing 0.9 mg/ml benzyl alcohol), petrolatum based creams (e.g., USP hydrophilic ointments and similar creams, Unibase, Parke-Davis, for example), various types of pharmaceutically acceptable gels, and short chain alcohols and glycols (e.g., ethyl alcohol and propylene glycol). In another embodiment of the invention, topical formulations may also contain the peptide-copper complex encapsulated in liposomes to aid in the delivery of the peptide-copper complex to the hair follicle. Alternatively, the peptide-copper complex may be formulated in an instrument to deliver the compound via iontophoresis.

The peptide-copper complexes of this invention exhibit superior skin permeability when applied topically. This results in a greater effective dose to the treatment area, and

thus correspondingly greater stimulation of hair growth. In the practice of this invention, hydrophobic amino acids or amino acid derivatives are preferably used for administration by injection (such as intradermal injection), while hydrophilic amino acids or amino acid derivatives are used for topical administration. While the use of hydrophobic amino acids or amino acid derivatives generally enhance activity of the copper-peptide complexes of this invention, the use of hydrophilic amino acids or amino acids derivatives for topical administration is preferred due to the enhanced skin permeability associated therewith.

For purpose of illustration, Table 3 presents examples of suitable topical formulations within the context of the present invention. As used below, "% (w/w)" represents the weight percentage of a component based on the total weight of the formulation:

Table 3
Representative Topical Formulations

15	<u>Preparation A:</u>	
	Peptide-Copper Complex	1.0% (w/w)
	Hydroxy Ethyl Cellulose	3.0% (w/w)
	Propylene Glycol	20.0% (w/w)
20	Nonoxynol-9	3.0% (w/w)
	Benzyl Alcohol	2.0% (w/w)
	Aqueous Phosphate Buffer (0.2N)	71.0% (w/w)
	<u>Preparation B:</u>	
	Peptide-Copper Complex	1.0% (w/w)
25	Nonoxynol-9	3.0% (w/w)
	Ethyl Alcohol	96.0% (w/w)
	<u>Preparation C:</u>	
	Peptide-Copper Complex	5.0% (w/w)
	Ethyl Alcohol	47.5% (w/w)
30	Isopropyl Alcohol	4.0% (w/w)
	Propylene Glycol	20.0% (w/w)
	Lanoeth-4	1.0% (w/w)
	Water	27.5% (w/w)
	<u>Preparation D:</u>	
35	Peptide-Copper Complex	5.0% (w/w)
	Sterile Water	95.0% (w/w)
	<u>Preparation E:</u>	
	Peptide-Copper Complex	2.5% (w/w)
	Hydroxypropyl Cellulose	2.0% (w/w)
40	Glycerine	20.0% (w/w)
	Nonoxynol-9	3.0% (w/w)
	Sterile Water	72.5% (w/w)

Preparation F:

	Peptide-Copper Complex	0.5% (w/w)
	Sterile Water	16.5% (w/w)
	Propylene Glycol	50.0% (w/w)
5	Ethanol	30.0% (w/w)
	Nonoxynol-9	3.0% (w/w)

Preparation G:

	Peptide-Copper Complex	5.0% (w/w)
	Sterile Water	10.0% (w/w)
10	Hydroxypropyl Cellulose	2.0% (w/w)
	Propylene Glycol	30.0% (w/w)
	Ethanol	50.0% (w/w)
	Nonoxynol-9	3.0% (w/w)

The peptides of the present invention may be synthesized by either solution or solid phase techniques known to one skilled in the art of peptide synthesis. The general procedure involves the stepwise addition of protected amino acids to build up the desired peptide sequence. The resulting peptide may then be complexed to copper (at the desired molar ratio of peptide to copper) by dissolving the peptide in water, followed by the addition of copper chloride and adjusting the pH. A more detailed disclosure directed to the synthesis of the peptide-copper complexes of this invention, as well as the activity certain representative peptide-copper complexes, are presented below.

EXAMPLES

The following examples are offered by way of illustration, and not by way of limitation. To summarize the examples that follow, Example 1 discloses the general preparation of peptide-copper complexes of the present invention by chelating a peptide to copper in an aqueous solution. Examples 2-10 disclose the synthesis of peptides which may be chelated to copper to yield peptide-copper complexes. Examples 11-16 disclose the ability of representative peptide-copper complexes of this invention to stimulate hair growth.

Source of Chemicals

Chemicals and peptide intermediates utilized in the following examples may be purchased from a number of suppliers, including: Sigma Chemical So., St. Louis, Missouri; Peninsula Laboratories, San Carlos, California; Aldrich Chemical Company, Milwaukee, Wisconsin; Vega Biochemicals, Tucson, Arizona; Pierce Chemical Co., Rockford, Illinois; Research Biochemicals, Cleveland, Ohio; Van Waters and Rogers, South San Francisco, California; and Bachem, Inc., Torrance, California.

Example 1

Preparation of Peptide-Copper Complex

The peptide-copper complexes of the present invention may be synthesized by
5 dissolving the peptide in distilled water, followed by the addition of copper chloride
(e.g., 99.999% available from Chemical Dynamics, N.J.) and then adjusting the pH of
the solution to about 7.0. For example, copper complexes of glycyl-L-histidyl-L-
phenylalanine (GHF) with a molar ratio of peptide to copper of 1:1, 2:1, or greater (e.g.,
3:1), may be prepared by dissolving a given weight of GHF in distilled water (e.g., 50
10 mg/ml), and adding the desired molar amount of purified copper-chloride. The pH of
the resulting peptide solution is then adjusted to about 7.0 by the addition of, for
example, a sodium hydroxide solution. Alternatively, copper salts other than copper
chloride may be used, for example, copper acetate, copper sulfate or copper nitrate.

15

Example 2

Synthesis of Glycyl-L-Histidyl-L-Caprolactam

L(-)-3-amino- ϵ -caprolactam was dissolved in tetrahydrofuran (THF) then
• coupled with N^{α} -t-butyloxycarbonyl- N^{im} -benzyloxycarbonyl-L-histidine (N^{α} -BOC-
 N^{im} -CBZ-L-histidine) using isobutyl chloroformate and N-methylmorpholine in THF.
20 After two hours at -20°C and an additional hour at ambient temperature, the reaction
was quenched with 2N aqueous potassium bicarbonate. This product was extracted into
ethyl acetate, washed with 1M aqueous citric acid, and saturated sodium bicarbonate.
The organic phase was dried over anhydrous sodium sulfate. Filtration and evaporation
gave N^{α} -BOC- N^{im} -CBZ-L-histidyl-L-caprolactam.

25 The above compound was dissolved in 30% trifluoroacetic acid in
dichloromethane for 30 minutes, then evaporated, forming N^{im} -benzyloxycarbonyl-L-
histidyl-L-caprolactam. This was then dissolved in tetrahydrofuran, and isobutyl
chloroformate, N-methylmorpholine and benzyloxycarbonyl-glycine were added to form
benzyloxycarbonyl-glycyl- N^{im} -benzyloxycarbonyl-L-histidyl-L-caprolactam. This
30 product was recrystallized once from ethyl acetate then dissolved in acetic acid and
hydrogenated overnight in the presence of 10% Pd-C catalyst. The resultant glycyl-L-
histidyl-L-caprolactam was lyophilized from water several times, then purified by liquid
chromatography on a C-18 reverse-phase column to yield the peptide as a diacetate salt.

Example 3

Synthesis of L-Alanyl-L-Histidyl-L-Phenylalanine

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-histidine (9.74g, 25.0mmol) and N-methylmorpholine (5.8mL, 5.3g, 52.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2 min. phenylalanine benzyl ester tosylate (10.7g, 25.0mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 13.7g (87%) of the blocked dipeptide as a white semi-solid (R_f = 0.75, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

A solution of the t-butyloxycarbonyl protected dipeptide (12.9g, 20.6mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 13.3g (ca. 100% + entrained solvent) of the free-amino compound as a white solid: R_f = 0.49 (10% methanol/dichloromethane).

To a stirred solution of N-CBZ-L-alanine (6.03g, 27.0mmol) and N-methylmorpholine (3.3mL, 3.0g, 29.7mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.7mL, 3.9g, 28.4mmol). After 2min. a solution of the suitably protected dipeptide (11.4g, 21.8mmol) in tetrahydrofuran (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 100mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give the blocked tripeptide as a white solid (R_f = 0.55, 10% methanol/dichloromethane), which was recrystallized from 95% ethanol to give 12.6g (79%) of a free-flowing white powder: mp 147-147.5°C; Anal. Calcd. for C₄₁H₄₀N₅O₈: C, 67.39; H, 5.52; N, 9.58. Found: C, 66.78; H, 5.64; N, 9.24.

To a suspension of the blocked tripeptide (12.6g, 17.6mmol) in ethanol (150mL) was added water, until the mixture became very turbid (about 150mL). The resulting

mixture was shaken with palladium chloride (1.56g, 8.8mmol) under an atmosphere of hydrogen (5 atm) for 16h. The catalyst was removed by filtration through a plug of Celite® and the filtrate was concentrated to remove volatile organic materials. The remainder was lyophilized to give 8.30g of white powder. This material was dissolved in water, filtered through a 0.2m nylon membrane and lyophilized to give 6.27g (87%) of the desired tripeptide dihydrochloride as a free-flowing white powder: $[\alpha]_D^{25} -5.1^\circ$ (c 2.0, water); ^1H NMR (500MHz, DMSO- d_6) δ 8.71 (1H, d, $J = 7.9$), 8.49 (1H, d, $J = 7.8$), 8.21 (1H, s), 7.30-7.22 (4H, m), 7.20-7.15 (1H, m), 7.12 (1H, s), 4.54 (1H, br q, $J = 7.1$), 4.37 (1H, m), 3.86 (1H, q, $J = 6.8$), 3.12 (1H, dd, $J = 4.3, 13.8$), 3.05-2.90 (2H, m), 2.88 (1H, dd, $J = 9.5, 13.8$), 1.27 (3H, d, $J = 6.8$); ^{13}C NMR (125MHz, DMSO- d_6) δ 173.5, 169.9, 169.5, 138.1, 134.2, 130.5, 129.2, 128.2, 126.4, 117.8, 54.4, 52.5, 48.0, 36.8, 28.5, 17.2.

Example 4

15 Synthesis of Glycyl-L-Histidyl-L-Glutamic Acid

To a stirred solution of N^α -BOC- N^{im} -CBZ-L-histidine (9.74g, 25.0mmol) and N-methylmorpholine (5.8mL, 5.3g, 52.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2 min. glutamic acid dibenzyl ester tosylate (12.5g, 25.0mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C . At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO_3 (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 15.2g (87%) of the blocked dipeptide as a white semi-solid ($R_f = 0.74$, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

A solution of the t-butyloxycarbonyl protected dipeptide (15.1g, 21.6mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 14.8g (ca. 100% + entrained solvent) of the free-amino compound as a white solid: $R_f = 0.48$ (10% methanol/dichloromethane).

35 To a stirred solution of N-CBZ-glycine (5.23g, 25.0mmol) and N-methylmorpholine (3.0mL, 2.8g, 27.5mmol) in tetrahydrofuran (50mL) at -15°C was

added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2min. a solution of the suitably protected dipeptide (12.9g, 21.6mmol) in tetrahydrofuran (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 100mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and concentrated to a syrup, which was diluted with absolute ethanol, and kept overnight at -20°C. The resulting precipitate was collected on a filter to afford 9.93g (58%) of the blocked tripeptide as a white solid (*R_f* = 0.58, 10% methanol/dichloromethane): mp 114-116°C. Anal. Calcd. for C₄₃H₄₃N₅O₁₀: C, 65.39; H, 5.49; N, 8.87. Found: C, 64.93; H, 5.56; N, 8.41.

To a suspension of the blocked tripeptide (9.6g, 12.2mmol) in ethanol (150mL) was added water, until the mixture became very turbid (about 150mL). The resulting mixture was shaken with palladium chloride (2.22g, 12.5mmol) under an atmosphere of hydrogen (5 atm) for 16h. The catalyst was removed by filtration through a plug of Celite® and the filtrate was concentrated to remove volatile organic materials. The remainder was lyophilized to give 4.72g of white powder. This material was dissolved in water, filtered through a 0.2m nylon membrane and lyophilized to give 4.64g (93%) of the desired tripeptide dihydrochloride as a free-flowing white powder: [*a*]_D²⁰ -16.6° (c 2.0, water); ¹H NMR (500MHz, D₂O) δ 8.65 (1H, s), 7.35 (1H, s), 4.77 (1H, m), 4.46 (1H, m), 3.88 (2H, s), 3.28 (1H, dd, *J*=15.3, 6.1), 3.21 (1H, dd, *J*=15.3, 8.0), 2.47 (2H, m), 2.21 (2H, m), 2.00 (2H, m); ¹³C NMR (125MHz, D₂O) δ 179.9, 177.3, 174.3, 169.8, 136.5, 130.8, 120.4, 55.6, 54.9, 43.3, 32.8, 29.3, 28.5; Anal. Calcd for C₁₃H₂₁Cl₂N₅O₆: C, 37.69; H, 5.11; N, 16.91; Cl, 17.12. Found: C, 37.23; H, 5.07; N, 16.01; Cl, 17.95.

Example 5

Synthesis of Glycyl-L-Histidyl-L-Phenylalanine

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-histidine (9.74g, 25.0mmol) and N-methylmorpholine (5.8mL, 5.3g, 52.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2 min. phenylalanine benzyl ester tosylate (10.7g, 25.0mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M

citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 13.0g (83%) of the blocked dipeptide as a white semi-solid (R_f = 0.79, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

A solution of the t-butyloxycarbonyl protected dipeptide (12.9g, 20.6mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 12.3g (ca. 100% + entrained solvent) of the free-amino compound as a white solid: R_f = 0.50 (10% methanol/dichloromethane).

To a stirred solution of N-CBZ-glycine (5.23g, 25.0mmol) and N-methylmorpholine (3.0mL, 2.8g, 27.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2min. a solution of the suitably protected dipeptide (10.8g, 20.6mmol) in tetrahydrofuran (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 100mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 14.0g (95%) of the blocked tripeptide as a white solid (R_f = 0.64, 10% methanol/dichloromethane), which was recrystallized from absolute ethanol to give a free-flowing white powder.

To a suspension of the blocked tripeptide (6.0g, 8.3mmol) in ethanol (150mL) was added water, until the mixture became very turbid (about 150mL). The resulting mixture was shaken with palladium chloride (1.47g, 8.3mmol) under an atmosphere of hydrogen (5 atm) for 16h. The catalyst was removed by filtration through a plug of Celite® and the filtrate was concentrated to remove volatile organic materials. The remainder was lyophilized to give 1.46g of white powder. This material was dissolved in water, filtered through a 0.2m nylon membrane and lyophilized to give 1.38g (38%) of the desired tripeptide dihydrochloride as a free-flowing white powder: $[\alpha]_D^{25} -7.5^\circ$ (c 1.0, water); ¹H NMR (500MHz, D₂O) δ 8.59 (1H, s), 7.39-7.25 (5H, m), 7.21 (1H, s), 4.70 (1H, br t, J = 7), 3.80 (2H, s), 3.24 (1H, dd, J=14.0, 5.5), 3.16 (1H, dd, J=15.4, 6.9), 3.10 (1H, dd, J=15.4, 7.4), 3.03 (1H, dd, J=14.0, 9.1); ¹³C NMR (125MHz,

DMSO-d₆) d 172.7, 169.5, 166.0, 137.6, 133.3, 129.2, 128.9, 128.3, 126.5, 116.8, 53.9, 51.8, 40.1, 36.4, 27.3.

Example 6

5 Synthesis of Glycyl-L-Histidyl-L-Lysyl-L-Phenylalanine

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-lysine (9.5g, 25.0mmol) and N-methylmorpholine (5.8mL, 5.3g, 52.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.7mmol). After 2min. phenylalanine benzyl ester tosylate (10.7g, 25.0mmol) was added. The reaction mixture was stirred at
10 -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 17.76g
15 (ca. 100% + entrained solvent) of the blocked dipeptide as a white solid (R_f = 0.84, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

A solution of the t-butyloxycarbonyl protected dipeptide (15.4g, 25.0mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room
20 temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 100mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 15.8g (ca. 100% + entrained solvent) of the free-amino compound as a white semi-solid: R_f = 0.55 (10% methanol/dichloromethane).

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-histidine (9.74g, 25.0mmol) and N-methylmorpholine (3.0mL, 2.8g, 27.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.7mmol). After 2min. a solution of the suitably protected dipeptide (12.9g, 25.0mmol) in tetrahydrofuran (30mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At
30 this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 20.58g (93%) of the blocked tripeptide as a white semi-
35 solid (R_f = 0.67, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

A solution of the t-butyloxycarbonyl protected tripeptide (20.5g, 23.1mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 20.5g (ca. 100% + entrained solvent) of the free-amino compound as a white solid: $R_f = 0.51$ (10% methanol/dichloromethane).

To a stirred solution of N-CBZ-glycine (7.24g, 34.6mmol) and N-methylmorpholine (4.2mL, 3.9g, 38.1mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (4.7mL, 5.0g, 36.3mmol). After 2min. a solution of the suitably protected tripeptide (18.2g, 23.1mmol) in 1:1 tetrahydrofuran/dimethylformamide (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C . At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO_3 (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 21.6g (95%) of the blocked tetrapeptide as a white solid ($R_f = 0.85$, 10% methanol/dichloromethane), which was used in the following transformation without further purification.

To a suspension of the blocked tetrapeptide (21.5g, 21.9mmol) in ethanol (150mL) was added water, until the mixture became very turbid (about 125mL). The resulting mixture was shaken with palladium chloride (3.89g, 21.9mmol) under an atmosphere of hydrogen (5 atm) for 16h. The reaction mixture became clear within about 1/2h, which may indicate completion of the reaction. The catalyst was removed by filtration and the filtrate was evaporated to give 13.7g of colorless semi-solid. This material was dissolved in water and lyophilized to give 11.5g (94%) of the desired tetrapeptide dihydrochloride as a free-flowing white powder: $[\alpha]_D -12.4^{\circ}$ (c 2.0, H_2O); ^1H NMR (500MHz, D_2O) δ 8.72 (1H, d, $J=7.7$), 8.40 (1H, d, $J=7.8$), 8.00 (1H, s), 7.30-7.19 (5H, m), 7.01 (1H, s), 4.62 (1H, br q, $J=4.7$), 4.44 (1H, m), 4.22 (1H, br q, $J=4.9$), 3.58 (2H, s), 3.10-2.90 (4H, m), 2.72 (2H, t, $J=7.3$), 1.65-1.20 (6H, m).

Example 7

Synthesis of Glycyl-L-Histidyl-L-Lysyl-L-Phenylalanyl-L-Phenylalanine

To a stirred solution of N^{α} -BOC-L-phenylalanine (10.6g, 40.0mmol) and N-methylmorpholine (4.8mL, 4.5g, 44.0mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (5.5mL, 5.7g, 42.0mmol). After 2min. a solution prepared

by mixing phenylalanine benzyl ester tosylate (17.1g, 40.0mmol), tetrahydrofuran (50mL), and N-methylmorpholine (4.4mL, 4.0g, 40.0mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 19.8g (98%) of the blocked dipeptide as a white solid (R_f = 0.98, 10% methanol/dichloromethane).

10 A solution of the t-butyloxycarbonyl protected dipeptide (19.7g, 39.2mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 100mL). The combined extracts were dried over sodium sulfate, filtered, and
15 evaporated to give 19.3g (ca. 100% + entrained solvent) of the free-amino compound : R_f = 0.65 (10% methanol/dichloromethane).

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-lysine (15.2g, 40.0mmol) and N-methylmorpholine (4.8mL, 4.5g, 44.0mmol) in tetrahydrofuran (100mL) at -15°C was added isobutyl chloroformate (5.5mL, 5.7g, 42.0mmol). After 2min. the protected
20 dipeptide (15.8g, 39.2mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was
25 dried over sodium sulfate, filtered, and evaporated to give 29.9g (98%) of the blocked tripeptide as a white solid (R_f = 0.84, 10% methanol/dichloromethane).

A solution of the t-butyloxycarbonyl protected tripeptide (15.4g, 25.0mmol) in 35% trifluoroacetic acid/dichloromethane (300mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M
30 aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 100mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 28.7g (ca. 100% + entrained solvent) of the free-amino compound as a fluffy white solid: R_f = 0.72 (10% methanol/dichloromethane).

To a stirred solution of N^α-BOC-N^{im}-CBZ-L-histidine (15.6g, 40.0mmol) and
35 N-methylmorpholine (4.8mL, 4.5g, 44.0mmol) in tetrahydrofuran (80mL) at -15°C was added isobutyl chloroformate (5.5mL, 5.7g, 42.0mmol). After 2min. a solution of the

suitably protected tripeptide (12.9g, 25.0mmol) in dimethylformamide (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 29.1g (72%) of the blocked tetrapeptide as a white solid (R_f = 0.97, 10% methanol/dichloromethane).

A solution of the t-butyloxycarbonyl protected tetrapeptide (29.1g, 28.0mmol) in 35% trifluoroacetic acid/dichloromethane (300mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 28.4g (ca. 100% + entrained solvent) of the free-amino compound as a white solid.

To a stirred solution of N-CBZ-glycine (7.32g, 35.0mmol) and N-methylmorpholine (4.2mL, 3.9g, 38.1mmol) in tetrahydrofuran (100mL) at -15°C was added isobutyl chloroformate (4.8mL, 5.0g, 36.7mmol). After 2min. a solution of the suitably protected tetrapeptide (26.3g, 28.0mmol) in 1:1 tetrahydrofuran/dimethylformamide (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 27.3g (87%) of the blocked pentapeptide as a white solid (R_f = 0.95, 10% methanol/dichloromethane).

To a suspension of the blocked pentapeptide (27.3g, 24.2mmol) in ethanol (200mL) was added water, until the mixture became very turbid (about 100mL). The resulting mixture was shaken with palladium chloride (4.3g, 24.4mmol) under an atmosphere of hydrogen (5 atm) for 16h. The reaction mixture became clear within about 1/2h, which may indicate completion of the reaction. The catalyst was removed by filtration and the filtrate was evaporated to give 14.6g (82%) of the desired pentapeptide dihydrochloride as a free-flowing white powder: $[\alpha]_D^{20}$ -12.1° (c 2.0, methanol).

Example 8Synthesis of Glycyl-L-Arginyl-L-Lysine

To a stirred solution of N^α-BOC-N⁸-nitro-L-arginine (8.0g, 25.0mmol) and N-methylmorpholine (3.0mL, 2.8g, 27.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2min. a solution of L-(N^{im}-CBZ)lysine benzyl ester hydrochloride (10.2g, 25.0mmol) and N-methylmorpholine (2.8mL, 2.5g, 25.0mmol) in tetrahydrofuran (30mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 16.3g (97%) of the blocked dipeptide as a white solid (R_f = 0.57, 10% methanol/dichloromethane).

A solution of the t-butyloxycarbonyl protected dipeptide (16.3g, 24.3mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred for 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 100mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 17.0g (ca. 100% + entrained solvent) of the free-amino compound as a white semi-solid: R_f = 0.12 (10% methanol/dichloromethane).

To a stirred solution of CBZ-glycine (7.32g, 35.0mmol) and N-methylmorpholine (4.2mL, 4.0g, 38.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (4.8mL, 5.0g, 36.8mmol). After 2min. a solution of the protected dipeptide (13.9g, 24.3mmol) in tetrahydrofuran (50mL) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 17.7g (95%) of the blocked tripeptide as a white solid (R_f = 0.51, 10% methanol/dichloromethane).

To a suspension of the blocked tripeptide (17.7g, 23.2mmol) in ethanol (250mL) was added water, until the mixture became very turbid (about 100mL). The resulting mixture was shaken with palladium chloride (4.25g, 24.0mmol) under an atmosphere of hydrogen (5 atm) for 18h. The catalyst was removed by filtration and the filtrate was

evaporated to give a white semi-solid. This material was dissolved in water, filtered through 0.45m nylon syringe filters, and lyophilized to give 10.2g (ca. 100%) of the desired tripeptide dihydrochloride as a white powder: $[\alpha]_D -14.6^\circ$ (c 2, water); ^1H NMR (500MHz, D_2O) δ 8.81(1H, br s), 8.30(1H, br s), 7.92(1H, br s), 4.37(1H, br s), 3.96(1H, d, $J=4.8$), 3.58(2H, d, $J=8.8$), 3.13(2H, br s), 2.74(2H, br s), 1.90-1.20(10H, m); ^{13}C NMR (125MHz, D_2O) δ 175.2, 170.5, 166.9, 157.5, 115.0, 53.7, 52.6, 31.4, 29.2, 27.8, 26.8, 25.0, 22.5, 19.1.

Example 9

10 L-Alanyl-L-Histidyl-L-Lysine

AHK may be obtained as an acetate salt from Bachem Bioscience Inc., Philadelphia, Pennsylvania (Catalog No. #1555). Alternatively, AHK may be synthesized as the dihydrochloride salt by the following procedure.

To a stirred solution of $\text{N}^\alpha\text{-BOC-N}^{\text{im}}\text{-CBZ-L-histidine}$ (9.74g, 25.0mmol) and 15 $\text{N-methylmorpholine}$ (5.8mL, 5.3g, 52.5mmol) in tetrahydrofuran (50mL) at -15°C was added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2min. ($\text{N-}\epsilon\text{-CBZ}$)-L-lysine benzyl ester hydrochloride (10.2g, 25.0mmol) was added. The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C . At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were 20 extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO_3 (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to give 17.2g (93%) of the blocked dipeptide as a white semi-solid ($R_f = 0.61$, 10% methanol/dichloromethane), which was used in the following transformation without 25 further purification.

A solution of the t-butyloxycarbonyl protected dipeptide (17.2g, 23.2mmol) in 35% trifluoroacetic acid/dichloromethane (150mL) was stirred 1/2h at room temperature. The resulting solution was concentrated in vacuo and neutralized with 2M aqueous potassium bicarbonate. The product was extracted into ethyl acetate (3 x 30 150mL). The combined extracts were dried over sodium sulfate, filtered, and evaporated to give 16.8g (ca. 100% + entrained solvent) of the free-amino compound as a white solid: $R_f = 0.26$ (10% methanol/dichloromethane).

To a stirred solution of N-CBZ-L-alanine (6.28g, 25.0mmol) and $\text{N-methylmorpholine}$ (3.0mL, 2.8g, 27.5mmol) in tetrahydrofuran (50mL) at -15°C was 35 added isobutyl chloroformate (3.4mL, 3.6g, 26.3mmol). After 2min. a solution of the above protected dipeptide (14.9g, 23.2mmol) in tetrahydrofuran (50mL) was added.

The reaction mixture was stirred at -15°C for 1.5h and then allowed to warm to 0°C. At this time the reaction was quenched by the addition of 2M aqueous potassium bicarbonate. The products were extracted with ethyl acetate (3 x 150mL). The combined extracts were washed with 1M citric acid (3 x 100mL), water, 2M KHCO₃ (3 x 100mL), water, and brine. The resulting solution was dried over sodium sulfate, filtered, and evaporated to a syrup, from which the blocked tripeptide was precipitated by dilution with 95% ethanol (300mL). The resulting material was collected on a filter, washed with 95% ethanol and dried to give a white solid: (*R_f* = 0.49, 10% methanol/dichloromethane); mp 151-153°C.

To a suspension of the blocked tripeptide (21.5g, 21.9mmol) in ethanol (200mL) was added water (about 200mL). The resulting mixture was shaken with palladium chloride (4.25g, 24.0mmol) under an atmosphere of hydrogen (5 atm) for 1h. The resulting mixture, in which the bulk of the material (other than the catalyst) became dissolved, was filtered and the filtrate was concentrated *in vacuo* to remove volatile organics. The remaining aqueous solution was lyophilized to give 10.88g of a white solid. This material was dissolved in water, filtered through a 0.2m nylon membrane, and, again, lyophilized to give 10.50g (99%) of the desired tripeptide dihydrochloride as a white powder: [α]_D -4.43°(c 3, H₂O); ¹H NMR (500MHz, DMSO-d₆) δ 8.73 (1H, d, J = 7.8), 8.45 (1H, d, J = 7.5), 8.09 (1H, s), 7.08 (1H, s), 4.59 (1H, dd, J = 5.4, 7.5), 4.12 (1H, m), 3.88 (1H, q, J = 6.9), 3.03 (1H, dd, J = 15.0, 4.8), 2.96 (1H, dd, J = 15.0, 7.7), 2.74 (2H, t, J = 7.5), 1.76-1.68 (1H, m), 1.66-1.51 (3H, m), 1.41-1.21 (2H, m), 1.32 (3H, d, J = 7.0); ¹³C NMR (125MHz, DMSO-d₆) δ 174.0, 169.9, 169.5, 134.2, 130.5, 117.8, 52.6, 52.5, 48.0, 38.4, 30.3, 28.2, 26.5, 22.4, 17.2.

25

Example 10

Synthesis of Peptide-Copper Complexes at Various Molar Ratios of Peptide to Copper

A. Peptide-Copper Complex at a 2:1 Molar Ratio

A solution of AHK was prepared by dissolving 2.6954 (0.0065 mole) of the AHK acetate (Bachem Bioscience Inc.) in approximately 10 ml of distilled water. The initial pH of this AHK solution was 6.71. Separately, a solution of copper(II) chloride was prepared by dissolving 0.4479 gm (0.0033 mole) of anhydrous copper(II) chloride in approximately 2.0 ml of distilled water. The copper(II) chloride solution was slowly added to the rapidly stirring AHK solution and the pH was constantly monitored with a pH meter. After all the copper(II) chloride solution was added, the combined solution pH was 3.83. The pH was then adjusted to 7.16 by the slow addition of a solution of

0.5 M NaOH, and the final volume was adjusted to 20.0 ml by addition of distilled water. This procedure yielded an aqueous solution containing AHK:Cu at a molar ratio of peptide to copper of 2:1, and at a concentration of 10 mg/ml. The solution was a dark blue-purple and had a characteristic absorption maximum at 563 to 580 nm.

5 B. Peptide-Copper Complex at a 2:1 Molar Ratio

AHK was prepared as the dihydrochloride salt as described in Example 9. A solution of AHK was prepared by dissolving 0.6388 gm (0.00146 mole) of L-alanyl-L-histidyl-L-lysine hydrochloride in approximately 5 ml of distilled water. The initial pH of this AHK solution was 2.45. Separately, a solution of copper(II) chloride was prepared
10 by dissolving 0.0967 gm (0.0007 mole) of anhydrous copper(II) chloride in approximately 1.0 ml of distilled water. The copper(II) chloride solution was slowly added to the rapidly stirring AHK solution and the pH was constantly monitored with a pH meter. After all the copper(II) chloride solution was added, the combined solution pH was 2.36. The pH was then adjusted to 7.05 by the slow addition of a solution of
15 0.5 M NaOH, and the final volume was adjusted to 20.0 ml by addition of distilled water. This procedure yielded an aqueous solution containing AHK:Cu at a molar ratio of peptide to copper of 2:1, and at a concentration of 10 mg/ml. The solution was a dark blue-purple and had a characteristic absorption maximum at 563 to 580 nm.

C. Peptide-Copper Complex at a 1.1:1 Molar Ratio

AHK was prepared as the dihydrochloride salt as described in Example 9. A solution of AHK was prepared by dissolving 1.6144 gm (0.0037 mole) of L-alanyl-L-histidyl-L-lysine hydrochloride in approximately 10 ml of distilled water. The initial pH of this AHK solution was 2.70. Separately, a solution of copper(II) chloride was prepared by dissolving 0.4267 gm (0.0032 mole) of anhydrous copper(II) chloride in
25 approximately 2.0 ml of distilled water. The copper(II) chloride solution was slowly added to the rapidly stirring AHK solution and the pH was constantly monitored with a pH meter. After all the copper(II) chloride solution was added, the combined solution pH was 2.14. The pH was then adjusted to 6.89 by the slow addition of a solution of 0.5 M NaOH, and the final volume was adjusted to 20.0 ml by addition of distilled
30 water. This procedure yielded an aqueous solution containing AHK:Cu at a molar ratio of peptide to copper of 1.1:1, and at a concentration of 7.5 mg/ml. The solution was a dark blue-purple and had a characteristic absorption maximum at 593 nm, and a broad peak at 586 to 607 nm.

D. Peptide-Copper Complex at a 1:1 Molar Ratio

A solution of AHK was prepared by dissolving 1.3007 gm (0.0007 mole) of AHK acetate (Bachem Bioscience Inc.) in approximately 5 ml of distilled water. The initial pH of this AHK solution was 6.95. Separately, a solution of copper(II) chloride was prepared by dissolving 0.0966 gm (0.0007 mole) of anhydrous copper(II) chloride in approximately 2.0 ml of distilled water. The copper(II) chloride solution was slowly added to the rapidly stirring AHK solution and the pH was constantly monitored with a pH meter. After all the copper(II) chloride solution was added, the combined solution pH was 2.91. The pH was then adjusted to 7.08 by the slow addition of a solution of 0.5 M NaOH, and the final volume was adjusted to 15.0 ml by addition of distilled water. This procedure yielded an aqueous solution containing AHK:Cu at a molar ratio of peptide to copper of 1:1, and at a concentration of 10 mg/ml. The solution was a dark blue-purple and had a characteristic absorption maximum at 595 nm, and a broad peak at 584 to 612 nm.

Example 11

Stimulation of Hair Growth by Representative Copper-Peptide Complexes

The following example illustrates the stimulation of hair growth in warm-blooded animals after intradermal injection of representative peptide-copper complexes of this invention.

In this experiment, the backs of C3H mice (60 days old, telogen hair growth phase) were closely clipped on day 1 using an electric clipper. A sterile saline solution containing the indicated peptide-copper complex was then injected intradermally (i.e., infiltrated under the skin) at two locations within the clipped areas of the mice. Injection at two locations provided two test locations within the clipped area of each mouse. Each injection (0.1 ml) contained between 0.36 to 0.55 mg of the peptide-copper complex within the sterile saline solution. A group of saline injected mice (0.1 ml) served as controls. Following injection of the peptide-copper complexes, indications of hair growth were seen within 10 days. The first visual signs were a darkening of the skin in a circular region surrounding the injection site. The size of this region is generally dose dependent, increasing with an increase in dose. The 0.1 ml injections used in this experiment produced a circle of hair growth measuring approximately 0.5 cm² to 5.0 cm² in diameter. Active hair growth occurred between 14-20 days following injection, with a maximum effect seen by day 29. Both the number of mice growing hair at the injection site and the diameter of the hair growth region were determined at day 21. A positive response was expressed as the number of mice exhibiting hair growth at the

injection sites compared to the total number of mice injected in the study. The results of this experiment are presented in Table 4 below (the day of onset is the day at which hair follicle pigmentation was first observed):

Table 4

5 Stimulation of Hair Growth by Peptide-Copper Complexes

<u>Peptide-Copper Complex</u>	<u>Molar Ratio</u> <u>(peptide to</u> <u>copper)</u>	<u>Dose</u> <u>(mg/injection)</u>	<u>Number of</u> <u>Animals</u> <u>Growing Hair</u>	<u>Day of</u> <u>Onset</u>
GHKF:Cu	2:1	0.36 mg	4/5	10
PHKF:Cu	2:1	0.43 mg	5/5	10
(N-methyl)GHKVFV:Cu	2:1	0.55 mg	5/5	10
GHKVF:Cu	2:1	0.43 mg	5/5	10
SALINE	-	-	0/5	NA

Example 12

Stimulation of Hair Growth by Representative Peptide-Copper Complexes

10 The following example illustrates the stimulation of hair growth in warm-blooded animals after intradermal injection of representative peptide-copper complexes of this invention.

As in Example 11 above, the backs of C3H mice (60 days old, telogen hair growth phase) were closely clipped on day 1 using an electric clipper. A sterile saline solution containing the indicated peptide-copper complex was then injected intradermally (i.e., infiltrated under the skin) at two locations within the clipped areas of the mice. Injection at two locations provided two test locations within the clipped area of each mouse. Each injection (0.1 ml) contained between 0.75 to 1.5 mg of the peptide-copper complex within the sterile saline solution. A group of saline injected mice (0.1 ml) served as controls. Following injection of the peptide-copper complexes, indications of hair growth were seen within 10 days. The first visual signs were a darkening of the skin in a circular region surrounding the injection site. The size of this region is generally dose dependent, increasing with an increase in dose. The 0.1 ml injections used in this experiment produced a circle of hair growth measuring approximately 0.5 cm² to 5 cm² in diameter. Active hair growth occurred between 14-20 days following injection, with a maximum effect seen by day 29. Both the number of mice growing hair at the injection site and the diameter of the hair growth region were determined at day 21. A positive response was expressed as the number of mice exhibiting hair growth at the injection

sites compared to the total number of mice injected in the study. The results of this experiment are presented in Table 5.

Table 5
Stimulation of Hair Growth by Peptide-Copper Complexes

<u>Peptide-Copper Complex</u>	<u>Molar Ratio (peptide to copper)</u>	<u>Dose (mg/injection)</u>	<u>Number of Animals Growing Hair</u>	<u>Area of Hair Growth</u>
PHK:Cu	2:1	1.00	2/5	> 1 cm diameter
GHL:Cu	2:1	1.50	3/4	> 1 cm diameter
GHE:Cu	2:1	1.50	2/4	> 1 cm diameter
PHA:Cu	2:1	1.50	1/4	< 1 cm diameter
PHF:Cu	2:1	0.75	4/4	> 1 cm diameter
PHL:Cu	2:1	1.50	2/4	< 1 cm diameter
AHK:Cu	2:1	0.75	1/4	< 1 cm diameter
AHK:Cu	2:1	1.50	4/4	> 1 cm diameter
VHK:CU	2:1	0.75	3/4	< 1 cm diameter
VHK:CU	2:1	1.50	4/4	> 1 cm diameter

5

Example 13
Stimulation of Hair Growth by Peptide-Copper Complexes
Containing D-Amino Acids

10 This example illustrates the stimulation of hair growth in warm-blooded animals by intradermal injection of AHK:Cu (1.1:1) utilizing a D-amino acids in place of the naturally occurring L-amino acid.

In this experiment, the backs of C3H mice (60 days old, telogen hair growth phase) were closely clipped on day 1 using an electric clipper. A sterile saline solution containing AHK:Cu (1.1:1), or AHK:Cu (1.1:1) containing a D-amino acid, was then
15 injected intradermally (i.e., infiltrated under the skin) at two locations within the clipped areas of the mice. Injection at two locations provided two test locations within the clipped area of each mouse. Each injection (0.1 ml) contained either 1.2 or 1.8 μ moles per injection of peptide-copper complex in the sterile saline solution. A group of saline
20 injected mice (0.1 ml) served as controls. Following injection of peptide copper complex, indications of hair growth were seen within 10 days. The first visual signs were a darkening of the skin in a circular region surrounding the injection site. The size

of this region is generally dose dependent, increasing with an increase in dose. The 0.1 ml injections used in this experiment produced a circle of hair growth measuring approximately 0.5 cm² to 5 cm² in diameter. Active hair growth occurred between 14-20 days following injection, with a maximum effect seen by day 29.

- 5 The degree of hair growth was determined by measuring the total area of hair growth at the two injection sites. The data from this experiment is presented in Table 6.

Table 6
Stimulation of Hair Growth by Peptide-Copper Complexes
Containing D-Amino Acids

<u>Peptide-Copper Complex</u>	<u>Molar Ratio (peptide to copper)</u>	<u>Dose (μmoles per injection)</u>	<u>Area of Hair Growth</u>
AHK:Cu	1.1:1	1.2	3.07 ± 0.76
AHK:Cu	1.1:1	1.8	3.24 ± 1.17
AH-(D)K:Cu	1.1:1	1.2	3.30 ± 0.30
AH-(D)K:Cu	1.1:1	1.8	3.94 ± 0.35
(D)A-HK:Cu	1.1:1	1.2	1.88 ± 0.57
(D)A-HK:Cu	1.1:1	1.8	2.68 ± 0.49

The table above illustrates that the substitution of D-amino acids for a corresponding L-amino acids dose not effect the hair growth activity of the peptide copper complexes.

15

Example 14
Stimulation of Hair Growth by Topical Application
of a Peptide-Copper Complex

- 20 This example illustrates the stimulation of hair growth in warm-blooded animals by topical application of a peptide-copper complex. In this experiment, telogen cycle female C3H mice (60-65 days old) were prepared by clipping their posterior dorsal region (i.e., day 1). Topical application of peptide-copper complexes was performed twice per day (Monday-Friday) using a cotton-tipped applicator which delivered approximately 0.1 ml per treatment. The topical formulation used in this experiment
- 25 contained the following components:

	Peptide copper Complex	0.1-0.5% (w/w)
	Sterile Water	16.9-16.5% (w/w)
	Propylene Glycol	50.0% (w/w)
	Ethanol	30.0% (w/w)
5	Nonoxynol-9	3.0% (w/w)

Topical application of the above formulation continued until the onset of follicle pigmentation, which proceeds the emergence of the hair shaft. Measurement of the degree of response was performed using digital image analysis at weekly intervals, beginning at day 14. Data was expressed as the percent treatment area response using the following equation:

$$\% \text{ treatment area} = (\text{growth area/treatment area}) \times 100$$

For comparison purposes to illustrate the effect of hydrophobic amino acid residues on hair growth after topical application, AHK:Cu was compared to AHF:Cu. In this experiment, topical formulations containing AHK:Cu (1.1:1) and AHF:Cu (1.1:1) were prepared at a concentration of 0.5% and 0.1% (w/w) as indicated above. Hair growth response (i.e., "Percent Treatment Area") was determined at day 20, day 27 and at day 34. The results of this experiment are presented in Table 7.

Table 7

<u>Peptide-Copper Complex</u>	<u>Molar Ratio (peptide to copper)</u>	<u>Concentration (% w/w)</u>	<u>Day</u>	<u>Percent Treatment Area</u>
AHK:Cu	1.1:1	0.1%	20	1.29 ± 1.29
AHK:Cu	1.1:1	0.1%	27	23.07 ± 18.84
AHK:Cu	1.1:1	0.1%	34	90.14 ± 2.96
AHK:Cu	1.1:1	0.5%	20	75.87 ± 7.64
AHK:Cu	1.1:1	0.5%	27	100
AHK:Cu	1.1:1	0.5%	34	100
AHF:Cu	1.1:1	0.1%	20	0.00
AHF:Cu	1.1:1	0.1%	27	0.00
AHF:Cu	1.1:1	0.1%	34	12.91 ± 12.91
AHF:Cu	1.1:1	0.5%	20	55.05 ± 17.44
AHF:Cu	1.1:1	0.5%	27	100
AHF:Cu	1.1:1	0.5%	34	100

The data presented in Table 7 illustrates that peptide-copper complexes containing hydrophilic residues (i.e., lysine amino acid of AHK:Cu) are more active in stimulating hair growth than similar peptides containing hydrophobic amino acid residues (i.e., the phenylalanine amino acid of AHF:Cu) following administration by topical administration. This is in contrast to administration by injection where peptide-copper complexes containing hydrophilic residues are less active than than similar peptides containing hydrophobic amino acid residues.

Example 15

Stimulation of Hair Growth by Intraperitoneal Injection of Peptide-Copper Complexes

The following experiment illustrates the maintenance of hair follicle viability (i.e., growth) by intraperitoneal (systemic) injection of the peptide-copper complex GHKVFV:Cu during treatment with the chemotherapeutic agent cytosine arabinoside (Ara-C).

In this experiment, Sprague-Dawley rat pups (age 8 days) were maintained in 4 litters (n=10/litter) for the duration of this study. On day 0, litters received intraperitoneal (IP) injections of GHKVFV:Cu (2:1) in a sterile saline solution, or a saline control (1 injection per animal, 0.1 ml per injection). On day 1, all animals began a series of 7 consecutive daily IP injections with Ara-C (50 mg/kg). On day 8, all animals were evaluated for the extent of hairloss (alopecia) using the following rating scale:

<u>Grade</u>	<u>Degree of Alopecia</u>
0	Normal (no loss of hair)
1	Slight thinning
2	Moderate thinning
3	Sparse hair cover
4	Total loss of hair

Ara-C injections caused significant hair loss by day 5-6 in most animals. In order to evaluate the effect of GHKVFV:Cu, the degree of hairloss was evaluated daily. Injection of GHKVFV:Cu at a dosage of 50 mg/kg caused a mild retention of hair on the body of the test animals. This was primarily seen on the head, with sparse remaining hair on the body. This was in contrast to the saline control (+Ara-C) group which showed total hair loss. Table 8 presents the results of this experiment as evaluated on day 8 using the previously described rating scale, with the "Degree of Alopecia" being expressed as the average response for all animals.

Table 8

<u>Peptide-Copper</u> <u>Complex</u>	<u>Dose per</u> <u>injection (mg)</u>	<u>Animal Dosage</u> <u>(mg/kg)</u>	<u>n =</u>	<u>Degree of</u> <u>Alopecia (mean)</u>
Saline Only	—	0.0	10	0.0
Saline + Ara-C	—	0.0	10	4.0
GHKVFV:Cu + Ara-C	1.00	50	10	3.0

5 The observation of retained hair was confirmed histologically on day 8. Of the animals receiving 50 mg/kg of GHKVFV:Cu, approximately 30-40% of dorsal hair was found to be in anagen, compared to 5-10% for animals receiving saline + Ara-C alone. Saline control animals not receiving Ara-C had 100% anagen follicles.

Example 16

10 Stimulation of Hair Growth by Intradermal Injection
of Peptide-Copper Complexes

The following experiment illustrates the localized maintenance of hair follicle viability (i.e., growth) by intradermal (local) injection of the peptide-copper complex AHK:Cu during treatment with the chemotherapeutic agent cytosine arabinoside (Ara-C).

15 In this experiment, Sprague-Dawley rat pups (age 8 days) were maintained in 5 litters (n=10-11/litter) for the duration of this study. On day 0, litters received intradermal (ID) injections of AHK:Cu (1:1) in a sterile saline solution, or a saline control (1 injection per animal, 0.05 ml per injection). Each litter contained 2 normal control animals where no AHK:Cu or Ara-C was administered (i.e., saline only). On day 20 1, designated animals began a series of 7 consecutive daily intraperitoneal (IP) injections with Ara-C (25 mg/kg). On day 10, all animals were evaluated for the extent of hairloss (alopecia) at the injection sites using the rating identified in Example 15.

25 Ara-C injections caused significant hair loss by day 5-6 in most animals. In order to evaluate the stimulatory effect of AHK:Cu, the degree of hairloss was evaluated at the injection site daily. AHK:Cu injection generally caused a retention of hair in a 0.25 cm radius around the injection site, most notably in the 0.1 to 0.5 mg dose groups. Table 9 presents the results as evaluated on day 10 using the previously described rating scale, with the the "Degree of Alopecia" being expressed as the average response seen at the 30 site of injection.

Table 9


<u>Peptide-Copper Complex</u>	<u>Dose per injection (mg)</u>	<u>Animal Dosage (mg/kg)</u>	<u>n =</u>	<u>Degree of Alopecia (mean)</u>
Saline Only	—	0.0	8	0.00
Saline + Ara-C	—	0.0	8	4.00
AHK:Cu + Ara-C	0.05	3.5	8	3.25
AHK:Cu + Ara-C	0.10	7.0	8	2.38
AHK:Cu + Ara-C	0.25	17.5	9	1.44
AHK:Cu + Ara-C	0.50	35.0	9	1.11

5 The observation of retained hair within the area of AHK:Cu injection was examined histologically. While normal appearing and functioning anagen hair follicles were seen at the injection site of AHK:Cu, follicles located away from the injection were dystrophic and non-functional (disruption of the integrity of inner and outer root sheaths, and displaced hair shafts). These data confirm the gross observations of normal hair follicle function within the site of AHK:Cu injection, and illustrate the stimulatory effect of AHK-Cu on the hair follicle which maintains the active growth cycle during chemotherapy treatment.

15 From the foregoing, it will be appreciated that, although specific embodiments of the invention have been described herein for purposes of illustration, various modifications may be made without deviating from the spirit and scope of the invention. Accordingly, the invention is not to be limited except as by the appended claims.

Claims

1. A composition for use as an active therapeutic substance comprising a peptide-copper complex having the structure:



wherein R_1 is an amino acid or amino acid derivative; R_2 is histidine, arginine or a derivative thereof; and R_3 is at least one amino acid or amino acid derivative joined to R_2 by a peptide bond, with the proviso that R_1 is not glycyl, alanyl, seryl or valyl when R_2 is histidyl or (3-methyl)histidyl and R_3 is lysine, lysyl-prolyl-valyl-phenylalanyl-valine, lysyl-valyl-phenylalanyl-valine, lysyl-tryptophan, or lysyl-(glycyl)₁₋₂-tryptophan, and with the further proviso that R_1 is not lysyl when R_2 is histidyl or (3-methyl)histidyl and R_3 is glycine, glycyl-prolyl-valyl-phenylalanyl-valine, glycyl-valyl-phenylalanyl-valine, glycyl-tryptophan, or glycyl-(glycyl)₁₋₂-tryptophan, and a pharmaceutically acceptable carrier or diluent.

2. The composition according to claim 1 wherein R_1 is an amino acid.
3. The composition according to claim 1 wherein R_2 is histidine.
4. The composition according to claim 1 wherein R_3 is at least one amino acid.
5. The composition according to claim 1 wherein R_3 is an amino acid.
6. The composition according to claim 1 wherein administration of the peptide-copper complex is by topical administration.
7. The composition according to claim 6 wherein R_1 is a hydrophilic amino acid.
8. The composition according to claim 6 wherein R_3 is a hydrophilic amino acid.

9. A composition for use as an active therapeutic substance comprising a peptide-copper complex having the structure:




wherein R_1 is an amino acid or an amino acid derivative; and R_2 is histidine, arginine or a derivative thereof, and a pharmaceutically acceptable carrier or diluent.

10. The composition according to claim 9 wherein R_1 is an amino acid.

11. The composition according to claim 9 wherein R_2 is histidine.

12. The composition according to claim 9 wherein R_1 is a hydrophilic amino acid.

13. A composition for use as an active therapeutic substance comprising a peptide-copper complex having the structure:



wherein R_1 is an amino acid or amino acid derivative; R_2 is histidine, arginine or a derivative thereof; and R_3 is a chemical moiety joined to R_2 by an amide bond, wherein R_3 is not an amino acid or amino acid derivative, and a pharmaceutically acceptable carrier or diluent.

14. The composition according to claim 13 wherein R_1 is an amino acid.

15. The composition according to claim 13 wherein R_2 is histidine.

16. The composition according to claim 13 wherein R_3 is selected from the group consisting of $-NH_2$, alkylamino moieties having from 1-20 carbon atoms, and arylamino moieties having from 6-20 carbon atoms.

17. The use of a peptide-copper complex according to any of claims 1-16 for the manufacture of a medicament for stimulating hair growth on an animal in need thereof.

18. The use according to claim 17 wherein the animal has a hair-loss affliction selected from the group consisting of androgenetic alopecia, alopecia areata, female pattern baldness and secondary alopecia.

19. The use according to claim 18 wherein the hair-loss affliction is androgenetic alopecia.

20. The use according to claim 18 wherein the hair loss affliction is secondary alopecia.

21. A method for stimulating hair growth on an animal in need thereof, comprising administering to the animal an effective amount of a peptide-copper complex according to any of claims 1-16.

22. The method of claim 18 wherein administration of the peptide-copper complex is by topical administration.

INTERNATIONAL SEARCH REPORT

International Application No
PCT/US 95/07626

A. CLASSIFICATION OF SUBJECT MATTER
IPC 6 A61K7/06

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 6 A61K

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	WO,A,88 08695 (PROCYTE CORPORATION) 17 November 1988 *Document*	1-22
A	WO,A,89 12441 (PROCYTE CORPORATION) 28 December 1989 *Document*	1-16
A	WO,A,91 07431 (PROCYTE CORPORATION) 30 May 1991 *Document*	1-22
A	EP,A,0 190 736 (IAMA INCORPORATED) 13 August 1986 *Document*	1-16
	--- -/--	

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents :

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

- "T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
- "X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
- "Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.
- "&" document member of the same patent family

Date of the actual completion of the international search

21 November 1995

Date of mailing of the international search report

- 1. 12. 95

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+ 31-70) 340-2040, Tx. 31 651 epo nl,
Fax (+ 31-70) 340-3016

Authorized officer

Luyten, H

INTERNATIONAL SEARCH REPORT

Inte. onal Application No
PCT/US 95/07626

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A	EP,A,0 189 182 (IAMA INCORPORATED) 30 January 1986 *Document* ---	1-16
A	WO,A,94 07448 (SKIN SCIENCE INCORPORATED) 14 April 1994 see page 29 - page 34; claims ---	1-16
A	CA,A,2 063 062 (COSMETICS CONTAINING RE-MINERALIZED WATER) 18 October 1992 see page 11 - page 12; claims ---	1-16
A	WO,A,94 03482 (ELLEM INDUSTRIA FARMACEUTICA S.R.L.) 17 February 1994 see page 36 - page 38; claims -----	1-16

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/07626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
WO-A-8808695	17-11-88	AT-T- 110255	15-09-94
		AU-B- 609819	09-05-91
		AU-B- 1729688	06-12-88
		DE-D- 3851203	29-09-94
		DE-T- 3851203	15-12-94
		EP-A- 0314755	10-05-89
		JP-T- 2500367	08-02-90
		NO-B- 175616	01-08-94
		US-A- 5135913	04-08-92
		US-A- 5120831	09-06-92
		US-A- 5177061	05-01-93
		US-A- 5214032	25-05-93
		US-A- 5348943	20-09-94
WO-A-8912441	28-12-89	AU-B- 633005	21-01-93
		AU-B- 3768789	12-01-90
		CA-A- 1335568	16-05-95
		DE-D- 68913739	14-04-94
		DE-T- 68913739	23-06-94
		EP-A- 0420914	10-04-91
		GR-A- 89100404	11-05-90
		JP-T- 3505872	19-12-91
		US-A- 5348943	20-09-94
WO-A-9107431	30-05-91	US-A- 5120831	09-06-92
		AU-B- 652136	18-08-94
		AU-B- 6878191	13-06-91
		CA-A- 2068324	14-05-91
		EP-A- 0500745	02-09-92
		JP-T- 5501567	25-03-93
EP-A-0190736	13-08-86	US-A- 4665054	12-05-87
		CA-A- 1294738	21-01-92
		DE-D- 3689380	27-01-94
		DE-T- 3689380	07-04-94
		JP-B- 7042311	10-05-95
		JP-A- 61191694	26-08-86
		US-A- 4767753	30-08-88
		US-A- 4810693	07-03-89
		US-A- 4877770	31-10-89

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No

PCT/US 95/07626

Patent document cited in search report	Publication date	Patent family member(s)	Publication date
EP-A-0190736		US-A- 5120831	09-06-92
		US-A- 5177061	05-01-93
		US-A- 5214032	25-05-93
		US-A- 5348943	20-09-94
EP-A-0189182	30-07-86	US-A- 4760051	26-07-88
		AT-T- 107310	15-07-94
		CA-A- 1286988	30-07-91
		DE-D- 3689909	21-07-94
		DE-T- 3689909	22-09-94
		EP-A- 0577151	05-01-94
		JP-B- 6074208	21-09-94
		JP-A- 61204132	10-09-86
		US-A- 4937230	26-06-90
WO-A-9407448	14-04-94	US-A- 5382431	17-01-95
		AU-B- 5142093	26-04-94
		CA-A- 2145527	14-04-94
		EP-A- 0673234	27-09-95
CA-A-2063062		NONE	
WO-A-9403482	17-02-94	AU-B- 4703393	03-03-94
		EP-A- 0656009	07-06-95